Abbott
Makes glucose monitors, cardiovascular devices, diagnostic tests, nutrition products, and branded generic medicines.
Something off on this page? Send us feedback.
Profile
Sells medical devices, diagnostic systems and tests, nutritional products, and branded generic medicines to healthcare providers and consumers worldwide. Medical Devices—anchored by FreeStyle Libre and cardiovascular platforms—is the largest business, while most sales come from outside the United States.
Develops and sells products across Medical Devices, Diagnostic Products, Nutritional Products, and Established Pharmaceutical Products. The largest segment and recent growth engine combines FreeStyle Libre continuous glucose monitoring with cardiovascular and neuromodulation platforms. Diagnostics spans Alinity laboratory systems, rapid and point-of-care tests, and cancer screening and precision-oncology testing added through Exact Sciences.
Nutrition includes Similac infant formula, Ensure and Glucerna adult nutrition, and Pedialyte. Established Pharmaceuticals markets branded generic medicines only outside the United States, principally in emerging markets.
Most sales come from outside the United States. Products face comprehensive regulation covering development, approval, manufacturing, labeling, pricing, reimbursement, and post-market surveillance, while overseas sales create foreign-exchange and trade-policy exposure.
Company facts
Key statistics
Year to date −9.5% · Average volume (30d) 8.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 13, 2026 | Wolfe Research | Reiterate | Outperform | $130 | |
| Jul 28, 2026 | UBS | Reiterate | Buy | $115 | $125 |
| Jul 20, 2026 | Benchmark Co. | Target | $120 | ||
| Jul 17, 2026 | Piper Sandler | Reiterate | Overweight | $115 | $118 |
| Jul 16, 2026 | BTIG | Target | $145 | $134 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026Q2 FY26 | $1.28 | $1.31 | +2.3% | $12.52B | $12.59B | +0.6% | +1.87% |
| Apr 16, 2026Q1 FY26 | $1.14 | $1.15 | +0.9% | $11.00B | $11.16B | +1.5% | +1.40% |
| Jan 22, 2026Q4 FY25 | $1.50 | $1.50 | 0.0% | $11.80B | $11.46B | −2.9% | −1.10% |
| Oct 15, 2025Q3 FY25 | $1.30 | $1.30 | 0.0% | $11.39B | $11.37B | −0.2% | −1.41% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $10.36B | $11.14B | $11.37B | $11.46B | $11.16B | $12.59B | |
| Gross profit | $5.44B | $6.29B | $6.34B | $6.54B | $6.28B | $7.30B | |
| Operating income | $1.69B | $2.05B | $2.06B | $2.25B | $1.84B | $1.78B | |
| Net income | $1.33B | $1.78B | $1.64B | $1.78B | $1.08B | $928.0M | |
| Diluted EPS | $0.76 | $1.01 | $0.94 | $1.02 | $0.62 | $0.53 | |
| Gross margin | 52.6% | 56.4% | 55.7% | 57.0% | 56.3% | 58.0% | |
| Operating margin | 16.3% | 18.4% | 18.1% | 19.6% | 16.5% | 14.2% |
Fiscal years (4-quarter sums)FY21 $43.08B · FY22 $43.65B · FY23 $40.11B · FY24 $41.95B · FY25 $44.33B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $5.60B · Total debt $32.61B · Total assets $109.22B · Shareholders' equity $51.11B
Dividends
Raised for 12 straight years — most recently to $0.63 from $0.59 in Jan 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 15, 2026 | Jul 15 | Aug 17 | $0.63 | |
| Apr 15, 2026 | Apr 15 | May 15 | $0.63 | |
| Jan 15, 2026 | Jan 15 | Feb 13 | $0.63 | raised from $0.59 |
| Oct 15, 2025 | Oct 15 | Nov 17 | $0.59 | |
| Jul 15, 2025 | Jul 15 | Aug 15 | $0.59 | |
| Apr 15, 2025 | Apr 15 | May 15 | $0.59 | |
| Jan 15, 2025 | Jan 15 | Feb 14 | $0.59 | raised from $0.55 |
| Oct 15, 2024 | Oct 15 | Nov 15 | $0.55 |
Ownership
Shares outstanding 1.73B · Float 1.72B · 99.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 152.56M | 8.82% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 113.75M | 6.57% | 13F | Aug 13, 2026 |
| State Street Corp | 80.93M | 4.68% | 13F | Aug 7, 2026 |
| Sixth Street Partners Management Company, L.P. | 59.67M | 3.45% | 13F | Aug 14, 2026 |
| Charles Schwab Investment Management Inc | 59.67M | 3.45% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Robert B. Ford | director, officer: CHAIRMAN AND CEO | −398,832 | $115.85 |
| Aug 11, 2026 | Louis H. Morrone | officer: EXECUTIVE VICE PRESIDENT | −5,850 | $109.83 |
| May 7, 2026 | John G. Stratton | director | +2,000 | $86.82 |
| Apr 27, 2026 | Daniel J. Starks | director | +10,000 | $92.65 |
| Apr 23, 2026 | Philip P. Boudreau | officer: EVP AND CFO | +2,200 | $91.50 |
Peers
- Medtronic
Broadest overlap: CGM, cardiac rhythm, structural heart, neuromodulation, and EP
- Boston Scientific
Competes in EP mapping, coronary stents, structural heart, CRM, and neuromod
- Dexcom
Head-to-head CGM rival in intensive insulin mgmt and OTC glucose biosensors
- Danaher
Diagnostics conglomerate: Cepheid POC, Radiometer blood gas, Beckman core lab
- Edwards Lifesciences
Structural heart (TAVR, mitral repair) and hemodynamic monitoring overlap
- BD
Rapid POC antigen, molecular syndromic panels, and microbiology overlap
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Dexcom | $90.77 | −0.06% | $34.27B | 35.9 | 32.4 | 6.9 | +13.1% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Edwards Lifesciences | $91.14 | +1.04% | $51.94B | 51.8 | 28.7 | 8.0 | +13.6% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Median | 37.1 | 19.8 | 4.7 | +8.7% |